©2024 Stanford Medicine
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Not Recruiting
Trial ID: NCT00535470
Purpose
To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol
ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or
AP ointment who did not achieve a complete response.
Official Title
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Stanford Investigator(s)
Sunil Arani Reddy
Clinical Associate Professor, Medicine - Oncology
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Eligibility
Inclusion Criteria:
- Patients must have completed the treatment phase of the Yaupon Therapeutics-sponsored
Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not
achieved a complete response.
Exclusion Criteria:
- Pregnant or nursing females, or males and females of childbearing potential, not using
an effective means of contraception
Intervention(s):
drug: 0.04% Mechlorethamine gel
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061